2022
DOI: 10.1093/schbul/sbac066
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Intranasal Oxytocin on Resting-state Effective Connectivity in Schizophrenia

Abstract: Objectives Evidence from several lines of research suggests the critical role of neuropeptide oxytocin in social cognition and social behavior. Though a few studies have examined the effect of oxytocin on clinical symptoms of schizophrenia, the underlying neurobiological changes are underexamined. Hence, in this study, we examined the effect of oxytocin on the brain’s effective connectivity in schizophrenia. Methods 31 male p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 73 publications
0
5
0
Order By: Relevance
“…In a controlled clinical trial involving individuals with schizophrenia, participants were administered nasal OXT (24 IU) or saline via a spray bottle. Subsequent magnetic resonance imaging (MRI) scans revealed improved social cognitive functioning following OXT application [ 59 ]. Notably, OXT comprises only nine amino acids, which may partially account for its extensive research focus [ 60 ].…”
Section: Discussionmentioning
confidence: 99%
“…In a controlled clinical trial involving individuals with schizophrenia, participants were administered nasal OXT (24 IU) or saline via a spray bottle. Subsequent magnetic resonance imaging (MRI) scans revealed improved social cognitive functioning following OXT application [ 59 ]. Notably, OXT comprises only nine amino acids, which may partially account for its extensive research focus [ 60 ].…”
Section: Discussionmentioning
confidence: 99%
“…This is a secondary data analysis of three studies conducted between 2013 and 2019 that included 87 patients with SCZ and 70 healthy volunteers (HV) in the age range of 18 to 50. [ 32 33 34 ] The eligibility criteria for the sample in the three studies are given in Supplementary Table S1 . All the studies were approved by the Institutional Ethics Committee (approval numbers: study 1 NIMHANS/85 th IEC/2013, dated May 17, 2013; study 2 NIMHANS/105 th IEC/2016, dated Jul 02, 2016; study 3 NIMHANS/105 th IEC/2016, dated Jul 02, 2016).…”
Section: Methodsmentioning
confidence: 99%
“…We administered Structured Clinical Interview for DSM-IV Disorders,[ 37 ] the Calgary Depression Scale for Schizophrenia,[ 38 ] and the Clinical Global Impression Scale,[ 39 ] to assess clinical symptoms. In two studies,[ 33 34 ] we used the Positive and Negative Syndrome Scale (PANSS), and in one study,[ 32 ] we used the Brief Psychiatric Rating Scale (BPRS) [ Supplementary Table 1 ]. Hence, we computed equipercentile scores of the PANSS using a validated method.…”
Section: Methodsmentioning
confidence: 99%
“…Likewise, exogenous sublingual OXT administration, in addition to clozapine treatment, reduced negative symptoms and maintained low positive symptoms in young adult patients with treatment-resistant schizophrenia [ 62 ]. Meanwhile, a single dose of intranasal OXT increased functional connectivity between the amygdala and left middle temporal gyrus (MTG), superior temporal sulcus (STS), and angular gyrus (AngG), associated with a reduction in negative symptoms, as well as the caudate and left supplementary motor area, precentral gyrus, and frontal inferior triangular gyrus, associated with greater cognitive insight and lower negative symptoms [ 63 , 64 ].…”
Section: The Oxytocin System In Schizophreniamentioning
confidence: 99%